SRPT
$16.69+0.04 (+0.24%)
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Recent News
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
KROS Stock: What to Know About Rinvatercept in DMD
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.